Cecil Nick

home / authors / cecil-nick

Cecil Nick is Vice President, Biotechnology, at PAREXEL Consulting.

Articles

Clinical And Cost Considerations Of Developing A Biosimilar

Keith Watson;Cecil Nick;Bruce Babbitt

September 1st 2010

Both biosimilar and generic drugs have an abbreviated approval process; however, the clinical trial requirements differ enormously.

Latest Updated Articles

Buy, Sell, Hold: Cell and Gene Therapy

Published: October 11th 2024 | Updated: October 18th 2024

Buy, Sell, Hold: Cell and Gene Therapy - Part 1

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 10th 2024 | Updated: September 18th 2024

CPHI Milan Announces 2024 CPHI Pharma Award Finalists

AAPS PharmSci 360: Challenges in Peptide-Based Drugs

Published: November 12th 2024 | Updated: November 29th 2024

AAPS PharmSci 360: Challenges in Peptide-Based Drugs

Published: November 13th 2024 | Updated: November 29th 2024

Risk-Based Development Supporting Process Qualification for Spray-Dried Dispersion

Improving Content Uniformity of Morphologically Challenging APIs by Excipient Choice

Published: November 22nd 2024 | Updated: November 29th 2024

Improving Content Uniformity of Morphologically Challenging APIs by Excipient Choice

The Pharmacy Advantage in Direct-to-Patient Clinical Supply

Published: November 22nd 2024 | Updated: November 29th 2024

The Pharmacy Advantage in Direct-to-Patient Clinical Supply

Editorial Advisory Board

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.